Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis (MS), the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
In the 1980s just 1 option had been available, but there are currently 12 that patients and providers need to choose between when creating a treatment plan for individuals with MS.
“It seems unlikely that any one drug will address all of the needs for all patients,” Richard Rudick, MD, director of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, said.
As a result, he added, treatment plans often need to be adjusted as time moves forward.
Bernd Kieseier, MD, professor of neurology at the Heinrich-Heine-University in Düsseldorf, Germany, added that the algorithm for treatment decisions has become rather complex.
Once the patient and physician decide to treat the disease, they then have to decide which option is the best, how to monitor if the treatment is working, and when they need to decide that the treatment is suboptimal and a new one should be implemented.
Although nearly all patients in later stages progress similarly, he said that the heterogeneity of the disease makes it difficult to predict the next events in individual patients during the early stages of MS.
“There is an urgent need for better understanding of monitoring…” Kieseier said.
Jeffrey Dunn, MD, FAAN, professor of clinical neurology and division chief of clinical neuroimmunology with the Department of Neurology and Neuroscience at Stanford University Medical Center, and Patricia Coyle, MD, FAAN, professor and director of the MS Comprehensive Care Center at Stony Brook University Medical Center, followed by discussing trial results for 2 drugs: dimethyl fumarate (tecfidera) and peginterferon beta-1a (plegridy).
In the 2-year clinical trial DEFINE, a randomized, double-blind, placebo-controlled, multicenter study, there was a 49% risk reduction of relapse compared with placebo and a 38% reduction in experienced sustained disability progression versus placebo.
Tecfidera also reported an 85% relative reduction in the number of new or newly enlarged T2 lesions, a 72% reduction in the number of new T1 hypointense lesions, and a 90% odds reduction in the number of Gd+ lesions compared with placebo.
Plegridy, an interferon beta for the treatment of patients with relapsing forms of MS, recorded a 36% relative reduction in annualized relapse rate, a 39% risk reduction in proportion of patients with relapses, a 38% risk reduction in proportion of patients with disability progression, a 67% reduction in new or newly enlarging T2 hyperintense lesions, and an 86% reduction in the number of Gd+ lesions.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More